Pfizer PFE Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenues: by Product | ||||||
| Abrysvo | $1.08B+46.0% | $1.03B+36.8% | $751M-29.9% | $828M-24.1% | $741M-28.4% | |
| Adcetris | $880M-16.2% | $908M-16.6% | $973M+13.1% | $1.03B+73.3% | $1.05B+235% | |
| All other Oncology | $1.33B+4.2% | $1.33B+10.9% | $1.31B+43.4% | $1.31B+25.1% | $1.28B+10.6% | |
| All other Primary Care | $2.9B+0.1% | $2.86B-6.6% | $2.85B-14.2% | $2.87B-11.7% | $2.9B-6.8% | |
| All other Specialty Care | $1.85B+17.1% | $1.76B+9.3% | $1.63B-20.2% | $1.54B-19.6% | $1.58B-5.6% | |
| Bosulif | $589M-9.4% | $611M-5.1% | $621M-5.2% | $632M-3.4% | $650M+1.4% | |
| Braftovi/Mektovi | $755M+20.4% | $717M+18.1% | $690M+21.5% | $661M+25.7% | $627M+27.7% | |
| Cibinqo | $302M+30.7% | $284M+32.1% | $269M+42.3% | $253M+55.2% | $231M+50.0% | |
| Comirnaty | $4.03B-27.5% | $4.37B-18.4% | $5.48B-25.3% | $5.75B-20.3% | $5.57B-34.6% | |
| Eliquis | $8.2B+13.2% | $7.96B+8.1% | $7.77B+8.8% | $7.38B+5.0% | $7.25B+4.9% | |
| Elrexfio | $324M+81.0% | $304M+130% | $287M+270% | $242M+505% | $179M+773% | |
| Enbrel (Outside the U.S. and Canada) | $625M-6.9% | $627M-9.1% | $631M-11.1% | $646M-13.8% | $671M-15.0% | |
| FSME-IMMUN/TicoVac | $337M+21.2% | $319M+13.9% | $306M+10.5% | $287M0.0% | $278M-3.5% | |
| Genotropin | $444M-0.2% | $446M-5.1% | $441M-14.9% | $432M-22.4% | $445M-13.1% | |
| Ibrance | $4.15B-3.2% | $4.12B-5.6% | $4.18B-4.8% | $4.21B-7.4% | $4.29B-8.0% | |
| Inlyta | $918M-4.4% | $923M-5.6% | $930M-6.9% | $951M-5.3% | $960M-5.3% | |
| Lorbrena | $1.11B+40.0% | $1.02B+39.8% | $934M+36.4% | $872M+36.7% | $790M+33.9% | |
| Nurtec ODT/Vydura | $1.53B+14.6% | $1.42B+12.7% | $1.41B+22.5% | $1.34B+27.5% | $1.33B+41.9% | |
| Octagam | $452M-13.4% | $418M-17.9% | $407M-15.4% | $515M+64.5% | $522M+89.8% | |
| Oncology Biosimilars | $1.45B+39.4% | $1.3B+25.5% | $1.14B-0.8% | $1.11B-5.4% | $1.04B-17.6% | |
| Orgovyx | $454M— | $421M— | $350M— | $295M— | —— | |
| Padcev | $2.11B+25.8% | $1.94B+22.2% | $1.88B+56.7% | $1.82B+131% | $1.67B+325% | |
| Pfizer CentreOne | $1.37B+17.9% | $1.35B+18.0% | $1.27B+7.3% | $1.21B+1.6% | $1.16B-4.9% | |
| Prevnar Family | $6.52B+2.2% | $6.49B+1.3% | $6.34B-2.1% | $6.4B-1.7% | $6.38B-3.2% | |
| Sulperazon (Outside the U.S. and Canada) | $688M+8.7% | $653M+2.7% | $653M+7.9% | $655M+14.7% | $633M+4.8% | |
| Talzenna | $192M+43.3% | $182M+55.6% | $159M+40.7% | $148M+52.6% | $134M+74.0% | |
| Tivdak | $148M+8.0% | $148M+12.1% | $153M+54.5% | $150M+131% | $137M+328% | |
| Tukysa | $483M+1.5% | $463M-3.5% | $473M+28.2% | $487M+98.8% | $476M+284% | |
| Vyndaqel family | $6.5B+12.0% | $6.38B+17.0% | $6.24B+28.1% | $6.09B+41.2% | $5.8B+53.8% | |
| Xeljanz | $1.14B+3.4% | $1.09B-6.9% | $1.11B-15.1% | $1.12B-24.9% | $1.1B-33.6% | |
| Xtandi | $2.18B+4.9% | $2.19B+7.6% | $2.17B+12.2% | $2.15B+18.8% | $2.08B+19.6% | |
| Zavicefta (Outside the U.S. and Canada) | $652M+9.4% | $637M+8.7% | $615M+9.8% | $609M+13.2% | $596M+14.6% | |
| Zithromax | $354M-19.2% | $400M-16.7% | $410M-19.4% | $420M-13.6% | $438M-3.9% | |
| Revenues: by Geography | ||||||
| International Developed Markets | $16.44B+2.5% | $16.19B+0.8% | $16.55B-5.9% | $16.27B-7.1% | $16.04B-13.2% | |
| International Emerging Markets | $9.44B+6.4% | $9.31B+4.9% | $9.06B+7.0% | $9.01B+8.2% | $8.88B+4.1% | |
| U.S. | $37.44B-0.3% | $37.08B-4.2% | $37.18B+8.1% | $38.55B+26.9% | $37.55B+29.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Pfizer break its business down?
- Pfizer (PFE) reports revenues: by product across 36 parts — Abrysvo, Adcetris, All Other Hospital and Biosimilars, All other Oncology and All other Primary Care. Each is extracted from the segment footnotes and tracked over time.
- Where does Pfizer's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Pfizer's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
